MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Pro

Altimmune's $225 Million Capital Raise: A Necessary Lifeline

2 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

LOBO's Latest Capital Raise: A Lifeline or a Dilution Trap

3 months ago

What's Driving Itron's Latest Capital Raise

4 months ago

What Does Erayak Power's Recent Capital Raise Really Mean for Investors

2 months ago

Is Whirlpool's $963 Million Capital Raise a Strategic Masterstroke or a Sign of Strain

4 months ago

Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report?

Altimmune (ALT) fell 11.3% since its last earnings report 30 days ago, as investors weigh pipeline updates and financial results.

ALT

Stock News•3 weeks ago

ALT and the Rise of Dual Agonists Targeting Liver Disease

Altimmune's pemvidutide faces pivotal 2026 trials in MASH and alcohol-related liver disease, testing its dual-agonist approach against single-pathway rivals.

ALT

Stock News•1 months ago

Agenus: Weighing The Clinical Progress Against The Company's Cash

Agenus faces a critical evaluation of its clinical development pipeline relative to its current cash position. Investors are weighing the company's ongoing research progress against the potential need...

AGEN

Stock News•2 months ago

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities

Altimmune closed a $225 million public offering of common stock and warrants, with an additional $225 million tranche available. The capital infusion secures operational funding through the anticipate...

ALT